09/2020: Case study with Evidentic
Evidentic and UGA Biopharma collaborated for a case study which was recently published on the website of Evidentic, “Aliquots: A New Solution to the Batch Variability Problem.”
To read the case study, which was developed with the help of our Team Leader Analytics/DSP Dr. Stephan Schultz, please click here.
Evidentic provides reference drugs in small quantities as ‘drug aliquots’, from EU licensed medicines. Its portfolio includes mAb drugs like Adalimumab, Bevacizumab, Ipilimumab, Pembrolizumab, and Trastuzumab, among others.
UGA Biopharma offers Cell line development services, specializing in the development of stable expressing CHO cell lines and cell media for the production of biologics and biosimilars for biopharmaceutical companies.
ContactUGA Biopharma GmbH
Phone: +49(0)3302 / 2024900